Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
August 05, 2019 07:50 ET
|
Arch Therapeutics, Inc.
Studies highlight antimicrobial activity for AC5 technology platform; AC5™ Topical Hemostat1 under Review by Notified Body FRAMINGHAM, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics,...
Arch Therapeutics to Provide Corporate Update at the 9th Annual LD Micro Invitational
May 30, 2019 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering
May 13, 2019 07:45 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH)(“Arch” or the “Company”), a developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference (SAWC) and Release of a New AC5TM Topical Gel Video
April 24, 2019 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., April 24, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of products for dermal science and biosurgical applications, today...
Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference
March 11, 2019 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
February 05, 2019 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics的AC5™外用水凝膠獲得美國食品藥品管理局（US FDA）上市前通知510(k)的批准函
December 26, 2018 19:00 ET
|
Arch Therapeutics, Inc.
美國馬薩諸塞州，弗雷明漢, Dec. 27, 2018 (GLOBE NEWSWIRE) -- 新型液體、凝膠和固體止血與傷口護理裝置開發者Arch Therapeutics,...
Arch Therapeutics的AC5™外用水凝胶获得美国食品药品管理局（US FDA）上市前通知510(k)的批准函
December 26, 2018 19:00 ET
|
Arch Therapeutics, Inc.
弗雷明汉，马萨诸塞州, Dec. 27, 2018 (GLOBE NEWSWIRE) -- 新型液体、凝胶和固体止血与伤口护理器械开发者Arch Therapeutics, Inc.（OTCQB：ARTH）（简称“Arch”或“公司”）于12月17日宣布，其AC5™...
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
December 20, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
December 17, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...